Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 115 articles:
HTML format



Single Articles


    June 2021
  1. DEBICKA-KUMELA M, Romanowska-Dixon B, Karska-Basta I, Kowal J, et al
    Diagnostic Algorithm for Conjunctival Melanocytic Lesions.
    Anticancer Res. 2021;41:3161-3167.
    PubMed     Abstract available


    May 2021
  2. KANG BS, Lim SC
    Fascin Regulates the Hippo Pathway and Is Important for Melanoma Development.
    Anticancer Res. 2021;41:2403-2410.
    PubMed     Abstract available


    April 2021
  3. BOCZAR D, Bagaria SP, Spaulding AC, Huayllani MT, et al
    Treatment Contraindications Based on Comorbidity Status in Patients With Melanoma in the United States.
    Anticancer Res. 2021;41:2067-2070.
    PubMed     Abstract available


    March 2021
  4. LEE Y, Park D
    Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
    Anticancer Res. 2021;41:1387-1399.
    PubMed     Abstract available


    February 2021
  5. EGGER EK, Stope MB, Recker F, Konsgen D, et al
    Lower Genital Tract Melanomas: Staging, Predictors of Outcome, and New Therapeutic Options.
    Anticancer Res. 2021;41:999-1004.
    PubMed     Abstract available


  6. BADAKHSHI H, Wang ZM, Li RJ, Ismail M, et al
    Survival and Prognostic Nomogram for Primary Gastrointestinal Melanoma (PGIM): A Population-based Study.
    Anticancer Res. 2021;41:967-974.
    PubMed     Abstract available


  7. LEE KM, An JH, Yang SJ, Park SM, et al
    Influence of Canine Macrophage-derived Extracellular Vesicles on Apoptosis in Canine Melanoma and Osteosarcoma Cell Lines.
    Anticancer Res. 2021;41:719-730.
    PubMed     Abstract available


  8. DEBICKA-KUMELA M, Romanowska-Dixon B, Karska-Basta I, Kowal J, et al
    The Evaluation of the Malignant Characteristics of Conjunctival Lesions Based on the Dermatoscopic Algorithm.
    Anticancer Res. 2021;41:895-903.
    PubMed     Abstract available


    January 2021
  9. MARKIEWICZ A, Donizy P, Elas M, OrLowska-Heitzmann J, et al
    Nuclear Pseudoinclusions and Intranuclear Grooves Have an Important Impact on the Long-term Survival of Patients With Uveal Melanoma.
    Anticancer Res. 2021;41:517-526.
    PubMed     Abstract available


    November 2020
  10. BORGOGNONI L, Pescitelli L, Gerlini G, Brandani P, et al
    Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non-melanoma Skin Cancer.
    Anticancer Res. 2020;40:6485-6492.
    PubMed     Abstract available


    September 2020
  11. HU JB, Ravichandran S, Rushing C, Beasley GM, et al
    Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.
    Anticancer Res. 2020;40:5245-5254.
    PubMed     Abstract available


  12. SANTOS LKB, Veras MDA, Marques KKG, DE Moraes Alves MM, et al
    Assessment of In Vitro Anti-melanoma Potential of Ephedranthus pisocarpus R.E.Fr.
    Anticancer Res. 2020;40:5015-5024.
    PubMed     Abstract available


    August 2020
  13. CZAJKA M, Zajkowska A, Gawlak M, Bujalska-Zadrozny M, et al
    Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung.
    Anticancer Res. 2020;40:4425-4444.
    PubMed     Abstract available


    July 2020
  14. CHOI S, Ha M, Lee JS, Heo HJ, et al
    Novel Prognostic Factor for Uveal Melanoma: Bioinformatics Analysis of Three Independent Cohorts.
    Anticancer Res. 2020;40:3839-3846.
    PubMed     Abstract available


  15. KAZIMIERCZAK U, Kolenda T, Kowalczyk D, Mackiewicz J, et al
    BNIP3L Is a New Autophagy Related Prognostic Biomarker for Melanoma Patients Treated With AGI-101H.
    Anticancer Res. 2020;40:3723-3732.
    PubMed     Abstract available


    June 2020
  16. BERUS T, Markiewicz A, Biecek P, Orlowska-Heitzman J, et al
    Clinical Significance of Nucleoli Cytomorphology Assessment in Patients With Uveal Melanoma.
    Anticancer Res. 2020;40:3505-3512.
    PubMed     Abstract available


  17. HUAYLLANI MT, Restrepo DJ, Boczar D, Avila FR, et al
    National Comprehensive Analysis of Characteristics of Acral Lentiginous Melanoma.
    Anticancer Res. 2020;40:3411-3415.
    PubMed     Abstract available


  18. CARLSSON A, Falk M
    Melanoma Risk Estimation Based on Objective Measures as a Complement to Self-Assessment.
    Anticancer Res. 2020;40:3325-3331.
    PubMed     Abstract available


    May 2020
  19. BATENI SB, Johns AJ, Gingrich AA, Gholami S, et al
    Elderly Age Is Associated With More Conservative Treatment of Invasive Melanoma.
    Anticancer Res. 2020;40:2895-2903.
    PubMed     Abstract available


  20. KOTOWSKI K, Supplitt S, Wiczew D, Przystupski D, et al
    3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells.
    Anticancer Res. 2020;40:2613-2625.
    PubMed     Abstract available


    April 2020
  21. SIMETIC L, Blazicevic K, Medugorac K, Golcic M, et al
    Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Anticancer Res. 2020;40:2157-2163.
    PubMed     Abstract available


  22. KACZOROWSKI M, Biecek P, Donizy P, Pieniazek M, et al
    ROCK1 and ROCK2 Are Down-regulated in Aggressive and Advanced Skin Melanomas - A Clinicopathological Perspective.
    Anticancer Res. 2020;40:1931-1942.
    PubMed     Abstract available


    February 2020
  23. HUAYLLANI MT, Bagaria SP, Restrepo DJ, Boczar D, et al
    Wide Excisional Surgery in Invasive Melanoma Treatment: Factors Driving Non-compliance With National Guidelines.
    Anticancer Res. 2020;40:1065-1069.
    PubMed     Abstract available


  24. HUAYLLANI MT, Bagaria SP, Restrepo DJ, Boczar D, et al
    Residual Tumor on Wide Excisional Margins After Treatment of Invasive Melanoma.
    Anticancer Res. 2020;40:1059-1063.
    PubMed     Abstract available


  25. BOCZAR D, Sisti A, Restrepo DJ, Huayllani MT, et al
    National Analysis of Patients With Ulcerated Melanoma in the United States.
    Anticancer Res. 2020;40:1055-1058.
    PubMed     Abstract available


  26. CONRAD A, Reinehr M, Holzmann D, Mangana J, et al
    Progressive Disease in Sentinel-negative Melanoma Patients: Biological Differences and Importance of Sentinel Lymph Node Biopsy.
    Anticancer Res. 2020;40:891-899.
    PubMed     Abstract available


  27. BIRKE M, Schope J, Wagenpfeil S, Vogt T, et al
    Association of Vitamin D Receptor Gene Polymorphisms With Melanoma Risk: A Meta-analysis and Systematic Review.
    Anticancer Res. 2020;40:583-595.
    PubMed     Abstract available


    January 2020
  28. REICHRATH J, Lindqvist PG, Pilz S, Marz W, et al
    Sunbeds and Melanoma Risk: Many Open Questions, Not Yet Time to Close the Debate.
    Anticancer Res. 2020;40:501-509.
    PubMed     Abstract available


  29. BROZYNA AA, Hoffman RM, Slominski AT
    Relevance of Vitamin D in Melanoma Development, Progression and Therapy.
    Anticancer Res. 2020;40:473-489.
    PubMed     Abstract available


    December 2019
  30. BOCZAR D, Restrepo DJ, Sisti A, Huayllani MT, et al
    Disparity on Unplanned Readmission in Melanoma Patients: A National Cancer Database Analysis.
    Anticancer Res. 2019;39:6877-6880.
    PubMed     Abstract available


  31. SARTO LE, DE Gois EP, DE Andrade GG, DE Almeida MS, et al
    Anticancer Potential of Palladium(II) Complexes With Schiff Bases Derived from 4-Aminoacetophenone Against Melanoma In Vitro.
    Anticancer Res. 2019;39:6693-6699.
    PubMed     Abstract available


  32. KIM G, Bhattarai PY, Oh CH, Choi HS, et al
    All-trans Retinoic Acid Overcomes Acquired Resistance to PLX4032 via Inhibition of PIN1 in Melanoma Cells.
    Anticancer Res. 2019;39:6537-6546.
    PubMed     Abstract available


    November 2019
  33. RESTREPO DJ, Huayllani MT, Boczar D, Sisti A, et al
    Biopsy Type Disparities in Patients With Melanoma: Who Receives the Standard of Care?
    Anticancer Res. 2019;39:6359-6363.
    PubMed     Abstract available


  34. BOCZAR D, Restrepo DJ, Sisti A, Huayllani MT, et al
    Analysis of Melanoma in African American Patients in the United States.
    Anticancer Res. 2019;39:6333-6337.
    PubMed     Abstract available


  35. HAO X, Yim J, Chang S, Schwartz E, et al
    Acral Lentiginous Melanoma of Foot and Ankle: A Clinicopathological Study of 7 Cases.
    Anticancer Res. 2019;39:6175-6181.
    PubMed     Abstract available


  36. ENDO M, Kanda M, Sawaki K, Shimizu D, et al
    Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.
    Anticancer Res. 2019;39:5903-5910.
    PubMed     Abstract available


    October 2019
  37. DRACA D, Mijatovic S, Krajnovic T, Kaluderovic GN, et al
    Synthetic Tubulysin Derivative, Tubugi-1, Against Invasive Melanoma Cells: The Cell Death Triangle.
    Anticancer Res. 2019;39:5403-5415.
    PubMed     Abstract available


    September 2019
  38. ZIPPEL D, Friedman-Eldar O, Rayman S, Hazzan D, et al
    Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
    Anticancer Res. 2019;39:4995-5001.
    PubMed     Abstract available


    August 2019
  39. VALENTINI V, Zelli V, Gaggiano E, Silvestri V, et al
    MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas.
    Anticancer Res. 2019;39:4085-4093.
    PubMed     Abstract available


    July 2019
  40. MARJANSKA A, Galazka P, Marjanski M, Wysocki M, et al
    Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma.
    Anticancer Res. 2019;39:3945-3947.
    PubMed     Abstract available


    June 2019
  41. KWON J, Kim YA, Lee C, Kim BH, et al
    Clinical Outcomes of Isolated Regional Lymph Node Recurrence in Patients With Malignant Cutaneous Melanoma.
    Anticancer Res. 2019;39:3147-3157.
    PubMed     Abstract available


    May 2019
  42. HEINO PJ, Myllari PH, Jahkola TA, Sintonen H, et al
    Long-Term Quality of Life of Melanoma Survivors Is Comparable to that of the General Population.
    Anticancer Res. 2019;39:2633-2640.
    PubMed     Abstract available


  43. MANTSO T, Vasileiadis S, Lampri E, Botaitis S, et al
    Hyperthermia Suppresses Post - In Vitro Proliferation and Tumor Growth in Murine Malignant Melanoma and Colon Carcinoma.
    Anticancer Res. 2019;39:2307-2315.
    PubMed     Abstract available


    April 2019
  44. YOO ES, Choo GS, Kim SH, Woo JS, et al
    Antitumor and Apoptosis-inducing Effects of Piperine on Human Melanoma Cells.
    Anticancer Res. 2019;39:1883-1892.
    PubMed     Abstract available


  45. ZHAO G, Bae JY, Zheng Z, Park HS, et al
    Overexpression and Implications of Melanoma-associated Antigen A12 in Pathogenesis of Human Cutaneous Squamous Cell Carcinoma.
    Anticancer Res. 2019;39:1849-1857.
    PubMed     Abstract available


  46. KLEINPOPPEN M, Moebius C, Grupp K, Kluwe L, et al
    Separating Response of Tumor and non-Tumor Cells to Drug In Vitro by Quantifying a Mutation.
    Anticancer Res. 2019;39:1777-1783.
    PubMed     Abstract available


    March 2019
  47. RADES D, Sehmisch L, Hansen HC, Dziggel L, et al
    Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM.
    Anticancer Res. 2019;39:1501-1505.
    PubMed     Abstract available


  48. HANSEN HC, Janssen S, Thieme C, Perlov A, et al
    Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses.
    Anticancer Res. 2019;39:1343-1346.
    PubMed     Abstract available


    February 2019
  49. MANTSO T, Anestopoulos I, Lamprianidou E, Kotsianidis I, et al
    Isothiocyanate-induced Cell Cycle Arrest in a Novel In Vitro Exposure Protocol of Human Malignant Melanoma (A375) Cells.
    Anticancer Res. 2019;39:591-596.
    PubMed     Abstract available


  50. SUKARI A, Nagasaka M, Alhasan R, Patel D, et al
    Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
    Anticancer Res. 2019;39:781-790.
    PubMed     Abstract available


    December 2018
  51. TROJAN SE, Piwowar M, Ostrowska B, Laidler P, et al
    Analysis of Malignant Melanoma Cell Lines Exposed to Hypoxia Reveals the Importance of PFKFB4 Overexpression for Disease Progression.
    Anticancer Res. 2018;38:6745-6752.
    PubMed     Abstract available


    November 2018
  52. ERDMANN M, Sigler D, Uslu U, Gohl J, et al
    Risk Factors for Regional and Systemic Metastases in Patients with Sentinel Lymph Node-negative Melanoma.
    Anticancer Res. 2018;38:6571-6577.
    PubMed     Abstract available


  53. SUZUKI H, Takano G, Hanai N, Nishikawa D, et al
    Primary Tumor Size Predicts Distant Metastasis of Mucosal Malignant Melanoma in Head and Neck.
    Anticancer Res. 2018;38:6485-6490.
    PubMed     Abstract available


  54. MATTILA K, Raanta P, Lahtela V, Pyrhonen S, et al
    Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
    Anticancer Res. 2018;38:6393-6397.
    PubMed     Abstract available


  55. PAMIDIMUKKALA NV, Leonard MK, Snyder D, McCorkle JR, et al
    Metastasis Suppressor NME1 Directly Activates Transcription of the ALDOC Gene in Melanoma Cells.
    Anticancer Res. 2018;38:6059-6068.
    PubMed     Abstract available


    October 2018
  56. ORANGES CM, Sisti G, Nasioudis D, Tremp M, et al
    Hard Palate Melanoma: A Population-based Analysis of Epidemiology and Survival Outcomes.
    Anticancer Res. 2018;38:5811-5817.
    PubMed     Abstract available


    August 2018
  57. TRESKOVA I, Topolcan O, Windrichova J, Simanek V, et al
    OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma.
    Anticancer Res. 2018;38:4907-4911.
    PubMed     Abstract available


  58. PLANSKA D, Kovalska J, Cizkova J, Horak V, et al
    Tissue Rebuilding During Spontaneous Regression of Melanoma in the Melanoma-bearing Libechov Minipig.
    Anticancer Res. 2018;38:4629-4636.
    PubMed     Abstract available


    July 2018
  59. MOSCHOS MM, Dettoraki M, Androudi S, Kalogeropoulos D, et al
    The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
    Anticancer Res. 2018;38:3817-3824.
    PubMed     Abstract available


  60. ARIMOTO A, Yamashita K, Hasegawa H, Sugita Y, et al
    Immunosuppression Induced by Perioperative Peritonitis Promotes Lung Metastasis.
    Anticancer Res. 2018;38:4333-4338.
    PubMed     Abstract available


  61. TUPY R, Mirka H, Mracek J, Priban V, et al
    Tumor-related Perfusion Changes in White Matter Adjacent to Brain Tumors: Pharmacodynamic Analysis of Dynamic 3T Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:4149-4152.
    PubMed     Abstract available


    June 2018
  62. PIRLAMARLA AK, Tang J, Amin B, Kabarriti R, et al
    Vulvar Melanoma with Isolated Metastasis to the Extraocular Muscles: Case Report and Brief Literature Review.
    Anticancer Res. 2018;38:3763-3766.
    PubMed     Abstract available


  63. MANTAS D, Damaskos C, Garmpis N, Dimitroulis D, et al
    Abdominal Emergencies in Patients with Stage IV Melanoma: The Role of Surgery: A Single-centre Experience.
    Anticancer Res. 2018;38:3713-3718.
    PubMed     Abstract available


  64. SAKAMOTO A, Kato K, Hasegawa T, Ikeda S, et al
    An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells.
    Anticancer Res. 2018;38:3273-3282.
    PubMed     Abstract available


  65. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Abstract available


    May 2018
  66. MOSCHOS MM, Moustafa GA, Lavaris A, Damaskos C, et al
    Depression in Choroidal Melanoma Patients Treated with Proton Beam Radiotherapy.
    Anticancer Res. 2018;38:3055-3061.
    PubMed     Abstract available


  67. AL-QURAYSHI Z, Crowther JE, Hamner JB, Ducoin C, et al
    Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
    Anticancer Res. 2018;38:2897-2901.
    PubMed     Abstract available


    March 2018
  68. WALTER L, Heinzerling L
    BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Anticancer Res. 2018;38:1335-1341.
    PubMed     Abstract available


    February 2018
  69. BURGARD B, Schope J, Holzschuh I, Schiekofer C, et al
    Solarium Use and Risk for Malignant Melanoma: Meta-analysis and Evidence-based Medicine Systematic Review.
    Anticancer Res. 2018;38:1187-1199.
    PubMed     Abstract available


  70. GRECO M, Arcidiacono B, Chiefari E, Vitagliano T, et al
    HMGA1 and MMP-11 Are Overexpressed in Human Non-melanoma Skin Cancer.
    Anticancer Res. 2018;38:771-778.
    PubMed     Abstract available


  71. REICHRATH J, Lindqvist PG, DE Gruijl FR, Pilz S, et al
    A Critical Appraisal of the Recent Reports on Sunbeds from the European Commission's Scientific Committee on Health, Environmental and Emerging Risks and from the World Health Organization.
    Anticancer Res. 2018;38:1111-1120.
    PubMed     Abstract available


    January 2018

  72. Cutaneous Melanoma. 1st Edition. A Pocket Guide for Diagnosis and Management.
    Anticancer Res. 2018;38:587.
    PubMed    


    December 2017
  73. PONTI G, Manfredini M, Greco S, Pellacani G, et al
    BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.
    Anticancer Res. 2017;37:7043-7048.
    PubMed     Abstract available


  74. RAPI V, Dogan A, Schultheis B, Hartmann F, et al
    Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
    Anticancer Res. 2017;37:6911-6920.
    PubMed     Abstract available


  75. DELGADO AF, Delgado AF
    Complete Lymph Node Dissection in Melanoma: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:6825-6829.
    PubMed     Abstract available


  76. WOZNIAK M, Peczek L, Czernek L, Duchler M, et al
    Analysis of the miRNA Profiles of Melanoma Exosomes Derived Under Normoxic and Hypoxic Culture Conditions.
    Anticancer Res. 2017;37:6779-6789.
    PubMed     Abstract available


  77. YANAROJANA M, Nararatwanchai T, Thairat S, Tancharoen S, et al
    Antiproliferative Activity and Induction of Apoptosis in Human Melanoma Cells by Houttuynia cordata Thunb Extract.
    Anticancer Res. 2017;37:6619-6628.
    PubMed     Abstract available


  78. BERUS T, Halon A, Markiewicz A, Orlowska-Heitzman J, et al
    Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review.
    Anticancer Res. 2017;37:6541-6549.
    PubMed     Abstract available


    November 2017
  79. MA YS, Hsiao YT, Lin JJ, Liao CL, et al
    Phenethyl Isothiocyanate (PEITC) and Benzyl Isothiocyanate (BITC) Inhibit Human Melanoma A375.S2 Cell Migration and Invasion by Affecting MAPK Signaling Pathway In Vitro.
    Anticancer Res. 2017;37:6223-6234.
    PubMed     Abstract available


  80. NAJEM A, Krayem M, Perdrix A, Kerger J, et al
    New Drug Combination Strategies in Melanoma: Current Status and Future Directions.
    Anticancer Res. 2017;37:5941-5953.
    PubMed     Abstract available


    October 2017
  81. PSINAKIS F, Katseli A, Koutsandrea C, Frangia K, et al
    Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.
    Anticancer Res. 2017;37:5719-5726.
    PubMed     Abstract available


  82. HU WP, Kuo KK, Senadi GC, Chang LS, et al
    Photodynamic Therapy Using Indolines-Fused-Triazoles Induces Mitochondrial Apoptosis in Human Non-Melanoma BCC Cells.
    Anticancer Res. 2017;37:5499-5505.
    PubMed     Abstract available


  83. GARMPIS N, Damaskos C, Garmpi A, Dimitroulis D, et al
    Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Anticancer Res. 2017;37:5355-5362.
    PubMed     Abstract available


    September 2017
  84. USLU U, Schliep S, Schliep K, Erdmann M, et al
    Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Anticancer Res. 2017;37:5033-5037.
    PubMed     Abstract available


  85. SUCKOW MA, Wolter WR, Duffield GE
    The Impact of Environmental Light Intensity on Experimental Tumor Growth.
    Anticancer Res. 2017;37:4967-4971.
    PubMed     Abstract available


    August 2017
  86. KIM YJ, Song SY, Kim W, Jeong SY, et al
    Feasibility of Postoperative Radiotherapy Using Conventional Fractionation for Lymph Node Metastasis from Cutaneous Melanoma.
    Anticancer Res. 2017;37:4239-4246.
    PubMed     Abstract available


    July 2017
  87. USLU U, Schuler G, Breuninger H
    Factors Influencing Disease Progression in Patients with Head and Neck Melanoma.
    Anticancer Res. 2017;37:3811-3816.
    PubMed     Abstract available


  88. FURUDATE S, Fujimura T, Kambayashi Y, Kakizaki A, et al
    Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Anticancer Res. 2017;37:3461-3471.
    PubMed     Abstract available


  89. NATH K, Nelson DS, Roman J, Putt ME, et al
    Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
    Anticancer Res. 2017;37:3413-3421.
    PubMed     Abstract available


  90. TANAKA T, Fujita M, Hasegawa H, Arimoto A, et al
    Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence.
    Anticancer Res. 2017;37:3863-3869.
    PubMed     Abstract available


    June 2017
  91. USLU U, Erdmann M, Schliep S, Dorrie J, et al
    Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.
    Anticancer Res. 2017;37:3243-3248.
    PubMed     Abstract available


  92. JANIK ME, Szlezak D, Surman M, Golas A, et al
    Diversified beta-2-adrenergic Receptor Expression and Action in Melanoma Cells.
    Anticancer Res. 2017;37:3025-3033.
    PubMed     Abstract available


  93. LAUBE F, Glanz D
    Modulation of Melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based Signaling for TFRC Up-regulation in Human Melanoma Cells.
    Anticancer Res. 2017;37:3001-3007.
    PubMed     Abstract available


    April 2017
  94. YAMAUCHI K, Mitsunaga T, Afroze SH, Uddin MN, et al
    Structure-Activity Relationships of Methylquercetin on Anti-migration and Anti-proliferation Activity in B16 Melanoma Cells.
    Anticancer Res. 2017;37:1575-1579.
    PubMed     Abstract available


    March 2017

  95. Melanoma Development. Molecular Biology, Genetics and Clinical Application.
    Anticancer Res. 2017;37:1544.
    PubMed    


  96. YOSHIKAWA S, Kiyohara Y, Otsuka M, Kondou R, et al
    Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
    Anticancer Res. 2017;37:1321-1328.
    PubMed     Abstract available


  97. LAWSON BO, Khong HT
    Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
    Anticancer Res. 2017;37:1365-1368.
    PubMed     Abstract available


  98. SPILIOPOULOS K, Peschos D, Batistatou A, Ntountas I, et al
    Immunohistochemical Study of Vasculogenic Mimicry and Angiogenesis in Melanocytic Tumors of the Eye and the Periocular Area.
    Anticancer Res. 2017;37:1113-1120.
    PubMed     Abstract available


    February 2017
  99. RYU SH, Heo SH, Park EY, Choi KC, et al
    Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes.
    Anticancer Res. 2017;37:607-614.
    PubMed     Abstract available


    January 2017
  100. SEHMISCH L, Schild SE, Rades D
    Development of a Survival Score for Patients with Cerebral Metastases from Melanoma.
    Anticancer Res. 2017;37:249-252.
    PubMed     Abstract available


  101. FORTIS SP, Anastasopoulou EA, Voutsas IF, Baxevanis CN, et al
    Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.
    Anticancer Res. 2017;37:143-148.
    PubMed     Abstract available


  102. NGUYEN AH, Detty SQ, Agrawal DK
    Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
    Anticancer Res. 2017;37:1-7.
    PubMed     Abstract available


    December 2016
  103. RADES D, Sehmisch L, Janssen S, Schild SE, et al
    Prognostic Factors After Whole-brain Radiotherapy Alone for Brain Metastases from Malignant Melanoma.
    Anticancer Res. 2016;36:6637-6640.
    PubMed     Abstract available


  104. NAFFOUJE SA, Naffouje R, Chen J, Salti GI, et al
    Validation and Enhancement of the Clinicopathological Melanoma Nomogram via Incorporation of a Molecular Marker in the Primary Tumor.
    Anticancer Res. 2016;36:6603-6610.
    PubMed     Abstract available


  105. SOLARI N, Gipponi M, Franco DS, Re F, et al
    Videoscopic Inguinal-iliac-obturator Lymph-node Dissection: New Videoscopic Technique for Regional Lymphadenectomy in Patients with Melanoma.
    Anticancer Res. 2016;36:6579-6583.
    PubMed     Abstract available


  106. YAN S, Holderness BM, Li Z, Seidel GD, et al
    Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.
    Anticancer Res. 2016;36:6449-6456.
    PubMed     Abstract available


  107. MANTSO T, Sfakianos AP, Atkinson A, Anestopoulos I, et al
    Development of a Novel Experimental In Vitro Model of Isothiocyanate-induced Apoptosis in Human Malignant Melanoma Cells.
    Anticancer Res. 2016;36:6303-6309.
    PubMed     Abstract available


    November 2016
  108. MARTON A, Kusz E, Kolozsi C, Tubak V, et al
    Vanillin Analogues o-Vanillin and 2,4,6-Trihydroxybenzaldehyde Inhibit NFkB Activation and Suppress Growth of A375 Human Melanoma.
    Anticancer Res. 2016;36:5743-5750.
    PubMed     Abstract available


    October 2016
  109. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Abstract available


    September 2016
  110. BASNET A, Saad N, Benjamin S
    A Case of Vanishing Brain Metastasis in a Melanoma Patient on Nivolumab.
    Anticancer Res. 2016;36:4795-8.
    PubMed     Abstract available


  111. DONIZY P, Biecek P, Halon A, Matkowski R, et al
    BILLCD8 - A Multivariable Survival Model as a Simple and Clinically Useful Prognostic Tool to Identify High-risk Cutaneous Melanoma Patients.
    Anticancer Res. 2016;36:4739-47.
    PubMed     Abstract available


  112. RAICA M, Jitariu AA, Cimpean AM
    Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma.
    Anticancer Res. 2016;36:4427-35.
    PubMed     Abstract available


    July 2016
  113. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Abstract available


  114. YAMASHITA K, Hasegawa H, Fujita M, Nishi M, et al
    Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer.
    Anticancer Res. 2016;36:3659-65.
    PubMed     Abstract available


    June 2016
  115. YAN S, Coffing BN, Li Z, Xie H, et al
    Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
    Anticancer Res. 2016;36:2871-80.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: